Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the commercial availability of Enrylaze® (a recombinant Erwinia asparaginase) in the UK. The medicine is indicated for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.[i]
Following the announcement that Porton Down Biopharma Limited (PBL) would cease manufacturing and supply of the alternative Erwinia-derived asparaginase,[ii] Jazz has collaborated with the Department of Health & Social Care Medicines Supply Team and UK Healthcare Professionals to support continuity of treatment for eligible patients who require second-line asparaginase.
“We are pleased to make this treatment commercially available across the UK following our agreement with the Department of Health & Social Care,” said Rebecca Catterick (pictured), General Manager, UK and Ireland at Jazz Pharmaceuticals. “This availability helps support continued access to a Erwinia-derived asparaginase treatment for eligible patients within the NHS”.
ALL and LBL are rare forms of blood cancer that most commonly impact children and young adults.[iii], [iv], [v] The overall incidence of ALL is estimated to be 1.1 per 100,000 persons per year in the United Kingdom,[vi] while LBL is a rare, fast-growing, aggressive subtype of non-Hodgkin’s lymphoma (NHL), which is very rare in adults and is most often seen in teenagers and young adults under the age of 35.9
Jazz’s recombinant Erwinia asparaginase was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for this patient population in January 2024.[vii] It is an Erwinia-(non-E. coli)-derived asparaginase developed using recombinant technology to deliver a scalable supply with a safety profile consistent with that of other studied comparator asparaginase preparations. [viii], [ix], [x], [xi] It may be administered by both intravenous infusion (IV) and intramuscular injection (IM) and is dosed on either alternate days (every 48 hours) or via a Monday/Wednesday/Friday dosing schedule.1
For a full list of side effects and information on dosage and administration, contraindications, and other precautions when using this medicine, please refer to the Summary of Product Characteristics.
References
[i] Medicines and Healthcare products Regulatory Agency. Enrylaze (cristantaspase). Summary of Product Characteristics. Published January 2024. Accessed 3 August 2026. https://mhraproducts4853.blob.core.windows.net/docs/19bb67d7dbcdd2cd8f93414960053a50079b508a
[ii] Clinigen. Erwinase / Porton Biopharma Limited Ceasing Manufacturing. Updated 27 April 2026. Accessed 3 August 2026. https://www.clinigengroup.com/important-update-on-erwinase-supply/.
[iii] National Cancer Institute. Adult acute lymphoblastic leukemia treatment (PDQ®)–Patient Version. Cancer.gov. Updated 12 May 2025. Accessed 3 August 18 2026. www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq.
[iv] National Cancer Institute. Childhood acute lymphoblastic leukemia treatment (PDQ®)–Patient Version. Cancer.gov. Updated 15 April 2025. Accessed 3 August 2026. https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq.
[v] Leukemia Foundation. Lymphoblastic lymphoma. Leukaemia.org.au. Updated 25 February 2026.Accessed 3 August 2026. https://www.leukaemia.org.au/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/lymphoblastic-lymphoma/.
[vi] Cancer Research UK. Acute lymphoblastic leukaemia statistics. Accessed 3 August 2026. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-all.
[vii] Medicines and Healthcare products Regulatory Agency. Enrylaze (cristantaspase). Public Assessment Report. Published January 2024. Accessed 3 August 2026. https://mhraproducts4853.blob.core.windows.net/docs/6dc2c6246e9d217c9763b79f9d6938446afa4ecc
[viii] Maese L, Rizzari C, Coleman R, et al. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? Pediatr Blood
Cancer. 2021;68(10):e29169. DOI 10.1002/pbc.29169.
[ix] Maese L, Mignon L, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023; 141 (7): 704–712.
[x] U.S. Food and Drug Administration. Rylaze prescribing information. Accessdata.fda.gov. Updated 2021. Accessed 3 August 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761179s000lbl.pdf.
[xi] Rylaze Product Monograph. Updated September 2, 2022. Accessed 3 August 2026. https://pdf.hres.ca/dpd_pm/00067274.PDF.
